1. ALLA AKTIER
  2. NYHETER
  3. LIDDS

LIDDS

Nyheter LIDDS Nyheter alla bolag

LIDDS’ Annual Report 2024 published

MARKN.

GOTHENBURG, SWEDEN – The 2024 Annual report of LIDDS AB (publ) is now available on the company website.

The annual report is available in Swedish in PDF format on the company website at: https://liddspharma.com/en/investors/financial-reports/.

Copies can be ordered from LIDDS AB, co Excore, Kungsportsavenyen 22, 411 36 Göteborg or by e-mail: info@liddspharma.com.

For additional information, please contact

Mats Wiking, CEO and CFO
Phone: +46 (0)70 620 04 00
E-mail: mats.wiking@liddspharma.com

LIDDS’ Certified Adviser is Redeye AB

LIDDS in brief:

LIDDS is a Swedish pharmaceutical company focused on the development of oncology drugs. LIDDS has a proprietary drug delivery technology, NanoZolid®, on which several projects are based. With NanoZolid, LIDDS can formulate drugs for local/intratumoral administration, with a maintained and controlled release and with minimal negative side-effects. In addition to these projects, LIDDS develops proprietary drug candidate NOV202 that have shown very good results in pre-clinical studies. The company is listed on Nasdaq First North Growth market.

Attachments

Årsredovisning 2024 LIDDS AB (publ)
Revisionsberättelse 2024 LIDDS AB (publ)

Datum 2025-05-06, kl 08:00
Källa MFN
Bifogade filer
Årsredovisning 2024 LIDDS AB (publ)
Revisionsberättelse 2024 LIDDS AB (publ)
Affiliate
100% cashback på aktiecourtage! Handla aktier på eToro och få tillbaka 100% av ditt courtage i 3 månader. Hur? Registrera dig här nu direkt för att ta del av erbjudandet.
Cashback är begränsad till högst $100. Värdet på dina investeringar kan gå upp eller ner. Du riskerar ditt kapital.